ABIVAX Société Anonyme (NASDAQ:ABVX) Reaches New 52-Week Low – Should You Sell?

ABIVAX Société Anonyme (NASDAQ:ABVX) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $8.27 and last traded at $8.39, with a volume of 8114 shares changing hands. The stock had previously closed at $8.50.

ABIVAX Société Anonyme Stock Up 0.7 %

The stock’s 50 day moving average is $10.17 and its 200 day moving average is $11.82.

Institutional Trading of ABIVAX Société Anonyme

Several institutional investors have recently added to or reduced their stakes in ABVX. Kennedy Capital Management LLC lifted its holdings in shares of ABIVAX Société Anonyme by 35.3% during the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after buying an additional 31,331 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after acquiring an additional 131,414 shares in the last quarter. abrdn plc raised its stake in ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after purchasing an additional 198,225 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the period. Finally, Walleye Capital LLC grew its position in shares of ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after purchasing an additional 80,807 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.